MAPT and Lewy body dementia: Ferreira et al. (2020)[73], in a large cohort of DLB patients (n = 417), have tested whether Aβ and Tau positivity, assessed as CSF amyloid-β 1–42 and phosphorylated tau, would determine a specific clinical DLB phenotype.